Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

Chengcheng Pu, Lei Lei, Fude Yang, Hong Deng, Jianhua Sheng, Zhening Liu, Shaohua Hu, Lina Wang, Bin Wu, Qijing Bo, Yoshifumi Inoue, Xin Yu, Chengcheng Pu, Lei Lei, Fude Yang, Hong Deng, Jianhua Sheng, Zhening Liu, Shaohua Hu, Lina Wang, Bin Wu, Qijing Bo, Yoshifumi Inoue, Xin Yu

Abstract

Introduction: Both the pharmacological characteristics of blonanserin and its related small sample size studies suggest that blonanserin could alleviate social and cognitive dysfunctions in patients with schizophrenia. However, no large sample size studies have been performed so far. This study aimed to investigate the effectiveness and safety of blonanserin in improving social and cognitive functions in patients with first-episode schizophrenia.

Methods and analysis: This is a prospective, multicentre, single-arm clinical trial. A total of 188 patients with first-episode schizophrenia will be enrolled and will undergo a 0-7 day washout period before blonanserin administration. Doses of blonanserin will first be set to 4 mg P.O. twice per day after meals and gradually increased to 8-16 mg/d P.O., depending on patient's age and symptoms, for 26 weeks. Maximum dose of blonanserin will not be exceeding 24 mg/day. The primary endpoint of the study is the changes of Personal and Social Performance (PSP) score in patients from baseline to week 26. Secondary endpoints include changes in MATRICS consensus cognitive battery (MCCB), Paced Auditory Serial Addition Test (PASAT), grooved pegboard test (GPT), Positive and Negative Syndrome Scale (PANSS) total score and PANSS 5-factor subscale scores. Other endpoints include changes of serum brain-derived neurotrophic factor (BDNF) at corresponding visits and MRI results. Moreover, incidence of adverse events, changes in endocrine and metabolic profiles, renal, hepatic and sexual functions and extrapyramidal symptoms will be strictly monitored and recorded.

Ethics and dissemination: The study was approved by the ethics committee of the leading site Peking University Sixth Hospital (No. 2018-18), and all included patients are requested to provide written informed consent before enrolment. The study will be conducted according to the principles of the Declaration of Helsinki and follow the principles for clinical research.

Trial registration number: NCT03784222.

Keywords: Adult psychiatry; PSYCHIATRY; Schizophrenia & psychotic disorders.

Conflict of interest statement

Competing interests: YI is an employee of Sumitomo Dainippon Pharma Co. LL is a former employees of Sumitomo Pharmaceutical (Suzhou) Co. Other authors report no conflict of interest.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow diagram.

References

    1. Association PBoCM . Guidelines for prevention and treatment of schizophrenia. 2nd Edition, 2015.
    1. Wang H, Xin Y. Psychiatry (7th edition, 2013.
    1. Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 2010;24:65–84. 10.2165/11202620-000000000-00000
    1. Schwartz JC, Diaz J, Pilon C, et al. . Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000;31:277–87. 10.1016/S0165-0173(99)00043-0
    1. Nakajima S, Gerretsen P, Takeuchi H, et al. . The potential role of dopamine D₃ receptor neurotransmission in cognition. Eur Neuropsychopharmacol 2013;23:799–813. 10.1016/j.euroneuro.2013.05.006
    1. Huang M, Kwon S, Oyamada Y, et al. . Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol Biochem Behav 2015;138:49–57. 10.1016/j.pbb.2015.09.011
    1. Tenjin T, Miyamoto S, Ninomiya Y, et al. . Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2013;9:587–94. 10.2147/NDT.S34433
    1. Zhang G, Stackman RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 2015;6:225. 10.3389/fphar.2015.00225
    1. Hida H, Mouri A, Mori K, et al. . Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. Neuropsychopharmacology 2015;40:601–13. 10.1038/npp.2014.207
    1. Hori H, Yamada K, Kamada D, et al. . Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. Neuropsychiatr Dis Treat 2014;10:527–33. 10.2147/NDT.S59861
    1. Miyake N, Miyamoto S, Takeuchi A. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: a randomized double-blind comparison with risperidone 2008.
    1. Penttilä M, Miettunen J, Koponen H, et al. . Association between the duration of untreated psychosis and short- and long-term outcome in schizophrenia within the Northern Finland 1966 birth cohort. Schizophr Res 2013;143:3–10. 10.1016/j.schres.2012.10.029
    1. Chang WC, Hui CLM, Tang JYM, et al. . Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study. Psychol Med 2013;43:1883–93. 10.1017/S0033291712002838
    1. Raghava JM, Mandl RCW, Nielsen Mette Ø, Nielsen M, et al. . Multimodal assessment of white matter microstructure in antipsychotic-naïve schizophrenia patients and confounding effects of recreational drug use. Brain Imaging Behav 2021;15:36–48. 10.1007/s11682-019-00230-4
    1. Berry C, Davies K, Woodford N, et al. . Survey of screening methods, rates and policies for the detection of carbapenemase-producing Enterobacteriaceae in English hospitals. J Hosp Infect 2019;101:158–62. 10.1016/j.jhin.2018.08.005
    1. Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull 2011;44:18–31.
    1. Tianmei S, Liang S, Yun'ai S, et al. . The Chinese version of the personal and social performance scale (PSP): validity and reliability. Psychiatry Res 2011;185:275–9. 10.1016/j.psychres.2010.05.001
    1. Hu M, Chen J, Li L, et al. . Semantic fluency and executive functions as candidate endophenotypes for the early diagnosis of schizophrenia in Han Chinese. Neurosci Lett 2011;502:173–7. 10.1016/j.neulet.2011.07.037
    1. Shi C, Kang L, Yao S, et al. . The MATRICS consensus cognitive battery (MCCB): Co-norming and standardization in China. Schizophr Res 2015;169:109–15. 10.1016/j.schres.2015.09.003
    1. Sakayori T, Tateno A, Arakawa R, et al. . Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients. Psychopharmacology 2021;238:1343–50. 10.1007/s00213-020-05698-3
    1. Wang S, Liu XB, Jiang T. 37 patients with schizophrenia treated with blonanserin. Herald of Medicine 2019;38:1292–4.
    1. Javed A, Charles A. The importance of social cognition in improving functional outcomes in schizophrenia. Front Psychiatry 2018;9:157. 10.3389/fpsyt.2018.00157
    1. Hashimoto T, Baba S, Ikeda H, et al. . Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: comparison with haloperidol. Eur J Pharmacol 2018;830:26–32. 10.1016/j.ejphar.2018.04.014
    1. Niitsu T, Hata T, Nishimoto M, et al. . A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: the roads study. Asian J Psychiatr 2020;53:102369. 10.1016/j.ajp.2020.102369

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera